What Happened: On February 14, 2017, Integra agreed to purchase Johnson & Johnson’s Codman neurosurgery business (excluding Codman’s neurovascular and drug deliver businesses) for $1.045 billion. Seven months later, on September 25, 2017, the Federal Trade Commission (FTC) agreed to clear the transaction subject to the parties divesting five neurosurgical tools and associated assets including the relevant intellectual property (IP), manufacturing technology and know-how, and research & development (R&D) information related to the five tools. Additionally the
The US FTC conditionally clears the transaction between two neurosurgical companies (Integra / Johnson & Johnson)
L'accès à cet article est réservé aux abonnés
Déjà abonné ? Identifiez-vous
L’accès à cet article est réservé aux abonnés.
Lire gratuitement un article
Vous pouvez lire cet article gratuitement en vous inscrivant.